Nanotechnology Now - Press Release: Hybrid Metal and Organic Nanoparticles for Targeting, Imaging, and Treating Cancer

Home > Press > Hybrid Metal and Organic Nanoparticles for Targeting, Imaging, and Treating Cancer

Abstract:
Using a set of three biocompatible polymers and a nanoparticle containing gadolinium, a team of investigators at the Colorado School of Mines has created a nanoparticle platform that has the potential to target, image, and treat cancer. Gadolinium ions are used widely in medical imaging because of their ability to dramatically boost magnetic resonance imaging (MRI) signals. However, gadolinium can be toxic, particularly to the kidneys, so researchers have examined numerous ways of creating gadolinium constructs that would shield this element from the body.

Hybrid Metal and Organic Nanoparticles for Targeting, Imaging, and Treating Cancer

Bethesda, MD | Posted on April 27th, 2009

Writing in the journal Biomacromolecules, a team of investigators led by Stephen Boyes, Ph.D., solved this biocompatibility problem while creating a versatile nanoparticle, platform-attaching tumor-targeting molecules, and therapeutic agents. The investigators started by creating gadolinium nanoparticles in which the gadolinium ions were stably constrained with an organic framework. Next, they grew a three-component polymer on a nanoparticle surface using a chemical process known as reversible addition-fragmentation chain transfer (RAFT). The resulting polymer coating proved in tests to be both biocompatible and highly stable. In addition, the coating contained various chemical groups that enabled the researchers to attach the anticancer agent methotrexate and a tumor-targeting peptide known as GRGDS. The researchers note that they could have chosen other targeting and therapeutic agents to attach to the polymer coating.

MRI experiments showed that these nanoparticles generated magnetic signals as strong as those produced by MRI contrast agents now in clinical use, but with one-third less contrast agent. In addition, the investigators showed that one of the polymer components produced a significant fluorescence signal, suggesting that these nanoparticles could provide clinically useful, dual-mode imaging capabilities. Tests with tumor cells grown in culture showed that these nanoparticles were effective at targeting tumor cells, with little uptake by normal cells. Once taken up by tumor cells, the nanoparticles were as effective at killing the cells as was methotrexate.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda, MD 20892-2580

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: